|Targets||Aurora Kinase | MEK|
|Description||BI-847325 is an orally bioavailable, and selective dual MEK/Aurora kinase inhibitor with IC50 of 3 nM, 25 nM, 15 nM, 25 nM, and 4 nM for Xenopus laevis Aurora B, human Aurora A and Aurora C, as well as human MEK1 and MEK2, respectively.|
|B0084-470824||10 mg||$169||In stock|
|Synonyms||BI-847325; BI 847325; BI847325.|
|Solubility||DMSO: 19mg/mL warmed(40.89mM); Ethanol: 1mg/mL(2.15mM); Water: <1mg/mL(<1mM)|
|Storage||3 years -20℃ powder; 6 months -80℃ in solvent|
|Shelf Life||2 years|
SCH1473759 (HCl salt)
The hydrochloride salt form of SCH-1473759, a new sub-nanomolar Aurora A/B inhibitor which could result in cell death by inhibiting Aurora kinases. It is proved...
Refametinib, also known as RDEA119, BAY 86-9766, is an orally bioavailable selective MEK inhibitor with potential antineoplastic activity. MEK inhibitor RDEA119...
RO5126766, also known as CH5126766, is a protein kinase inhibitor specific for the Raf and MEK mitogen-activated protein kinases (MAPKs) with potential anti-ne...
Reversine is a small molecule developed by the group of Peter G. Schultz, used for stem cell dedifferentiation. Reversine is also a novel Aurora kinases inhibit...
PD318088 is a MEK inhibitor
SMK-17 is a MEK1/2 inhibitor. It can inhibit MEK1 kinase activity in a non-ATP-competitive manner and it is highly selective to MEK1 and 2. SMK-17 can inhibit t...
RO4987655 is an orally active small molecule, targeting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), with potential antineoplastic activity. MEK ...
SNS-314 Mesylate is a potent and selective inhibitor of Aurora A, Aurora B and Aurora C with IC50 of 9 nM, 31 nM, and 3 nM, respectively. It is less potent to T...